Drug Trial Radar · NCT02573844
Pain Relief In Irritable Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 2015
Primary completion
Oct 2017
Study completion Jun 2018
Sponsor
- Lead sponsor
- Geophyt S.r.l.s.Industry
- Sponsor type
- Industry
- First posted
- Oct 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Proklama is effective in significative reduction of pain, other symptoms IBS's related, and improves quality of life concerning IBS disease.
Conditions
- Irritable Bowel Syndrome
Interventions
ProklamaDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recorded pain in a diary using a 11-points Numeric Rating Scale (NRS)Time frame: 24 h
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Policlinico San Matteo Pavia Fondazione IRCCS
Pavia, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.